Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
In a single-center, open-label, prospective, controlled, clinical study, it is planned to
include 300 patients hospitalized in the cardiology department of SBHI Penza regional
clinical hospital n.a. N.N. Burdenko. Recruitment of patients will be carried out at the
Department of Therapy of the Medical Institute of the Penza State University. Patients
meeting the inclusion criteria and not meeting the exclusion criteria will be included in the
study.
Initially, lipid-lowering treatment with atorvastatin is prescribed at a dose of 80 mg / day
from the first 24-96 hours of AMI in addition to the standard therapy.
If there is no achievement of the target level of LDL-C, ≤1.5 mmol / L after 5-6 weeks from
the AMI onset, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
Standard AMI treatment includes dual antiplatelet therapy, ACE inhibitors, beta-blockers (if
indicated). Prescription of proton pump inhibitors and nitrates is possible (if indicated).
The total follow-up is 96 weeks. Prescreening - 600 people; screening and randomization - 300
people. Parameters of electrical myocardial heterogeneity, myocardial deformation
characteristics, vascular rigidity, and quality of life will be assessed according to the
study plan.